Name: Jim Hollingshead
New title: President and CEO, BVI
Previous title: CEO, Insulet
Ophthalmic device business BVI has named former Insulet CEO Jim Hollingshead as its next leader, the company said Monday.
Hollingshead led Insulet, which sells the Omnipod insulin pump, for three years before resigning in 2025. Ashley McEvoy, the former head of Johnson & Johnson’s medtech business, replaced Hollingshead.
Hollingshead will now replace Shervin Korangy as CEO of BVI. The change in leadership comes after BVI raised $1 billion in capital last year. BVI is using the money to accelerate product innovation and expand its global footprint. The company makes cataract and retina surgery products from manufacturing sites in China, Europe, Mexico and the U.S.
RoundTable Healthcare Partners created BVI, which was originally called Beaver-Visitec International, by rolling up ophthalmology products acquired from Aspen Surgical, BD and Medtronic. The private equity firm acquired Aspen in 2006 and combined its ophthalmology business with eye disease assets bought from BD and Medtronic in 2010.
TPG Capital, another private equity firm, acquired BVI from RoundTable in 2016. As a TPG portfolio company, BVI has expanded in the intraocular lens market by acquiring PhysIOL Group and Benz Research & Development. BVI launched its first intraocular lens, the monofocal IPure, in the U.S. in 2020. The Food and Drug Administration approved the company’s Finevision HP trifocal intraocular lens last year.
BVI said in a statement that the Finevision approval brought its global leadership position in premium intraocular lenses to U.S. patients. Finevision has been CE marked since 2010 and has a history of use in the European Union and beyond. Alcon, Bausch & Lomb and J&J also sell intraocular lenses.
Korangy has been a constant throughout most of BVI’s TPG era, joining the company’s C-suite in 2017 and taking the CEO job in 2019. With Hollingshead joining BVI, Korangy has started working as an adviser to the company and begun a new role as senior adviser to TPG.
